Centrexion Therapeutics, which is developing non-opioid therapies for chronic pain, postponed its IPO on Thursday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16.
The Boston, MA-based company was founded in 2013 and had planned to list on the Nasdaq under the symbol CNTX. BofA Merrill Lynch, Leerink Partners and Evercore ISI were set to be the joint bookrunners on the deal.
